12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Seebri Breezhaler regulatory update

The European Commission approved Seebri Breezhaler glycopyrronium bromide from Novartis as a once-daily, inhaled maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). The inhaled long-acting muscarinic receptor antagonist...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >